loading page

Driving adoption of new technologies in biopharmaceutical manufacturing
  • +4
  • Gene Schaefer,
  • John Balchunas,
  • Timothy Charlebois,
  • John Erickson,
  • Roger Hart,
  • Sandeep B. Kedia,
  • Kelvin Lee
Gene Schaefer
National Institute for Innovation in Manufacturing Biopharmaceuticals

Corresponding Author:gene@udel.edu

Author Profile
John Balchunas
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile
Timothy Charlebois
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile
John Erickson
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile
Roger Hart
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile
Sandeep B. Kedia
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile
Kelvin Lee
National Institute for Innovation in Manufacturing Biopharmaceuticals
Author Profile

Abstract

The challenge of introducing new technologies into established industries is not a problem unique to the biopharmaceutical industry. However, it may be critical to the long-term competitiveness of individual manufacturers and, more importantly, the ability to deliver therapies to patients. This is especially true for new treatment modalities including cell and gene therapies. We review several barriers to technology adoption which have been identified in various public forums including business, regulatory, technology, and people-driven concerns. We also summarize suitable enablers addressing one or more of these barriers along with some suggestions for developing additional synergies.
30 Nov 2022Submitted to Biotechnology and Bioengineering
30 Nov 2022Review(s) Completed, Editorial Evaluation Pending
30 Nov 2022Submission Checks Completed
30 Nov 2022Assigned to Editor
23 Dec 2022Reviewer(s) Assigned
01 Feb 2023Editorial Decision: Revise Minor
18 Mar 20231st Revision Received
21 Mar 2023Submission Checks Completed
21 Mar 2023Assigned to Editor
21 Mar 2023Review(s) Completed, Editorial Evaluation Pending
21 Mar 2023Reviewer(s) Assigned
29 Mar 2023Editorial Decision: Accept